Qian J, Hyman BT, Betensky RA. Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design. JAMA Neurol. 2017 May 1;74(5):540-548. PubMed.

Comments

- Reisa Sperling
  Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School
- Posted: 18 Mar 2017
- News: Selecting Trial Participants Based on Tangle Pathology Might Improve Power
We will definitely look at responsiveness to treatment based on tau PET in A4 (in the subset with tau PET). I agree that staging with tau will likely yield a more homogenous group and more tau will be associated with faster decline (we are looking at this in vivo in the Harvard Aging Brain Study as well). However, we don’t really know what the optimal stage of treatment with anti-amyloid therapy will be, and it is conceivable that anti-amyloid mono-therapy will be more efficacious prior to widespread tau pathology.

View all comments by Reisa Sperling

Make a Comment

To make a comment you must login or register.

Paper

Tools

Comments

Make a Comment

This paper appears in the following:

News